Financials data is unavailable for this security.
Inc stmt in USDIncome statement in USD
Year on year
Hikma Pharmaceuticals PLC had little change in net income (from 431.00m to 421.00m) despite revenues that grew 9.06% from 2.34bn to 2.55bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 48.18% to 49.04%.
|Net profit margin||16.45%|
|Return on assets||9.87%|
|Return on equity||18.35%|
|Return on investment||13.05%|
Cash flow in USD
Hikma Pharmaceuticals PLC increased its cash reserves by 31.89%, or 103.00m. The company earned 638.00m from its operations for a Cash Flow Margin of 24.99%. In addition the company used 238.00m on investing activities and also paid 287.00m in financing cash flows.
|Cash flow per share||2.07|
|Price/Cash flow per share||7.96|
|Book value per share||8.69|
|Tangible book value per share||5.53|
Balance sheet in USD
|Total debt/total equity||0.3449|
|Total debt/total capital||0.2554|
Growth rates in USD
Year on year, growth in dividends per share increased 8.70% while earnings per share excluding extraordinary items fell by -0.22%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
|Div yield(5 year avg)||0.02%|
|Div growth rate (5 year)||11.07%|
|Payout ratio (TTM)||29.69%|
|EPS growth(5 years)||22.23|
|EPS (TTM) vs |
TTM 1 year ago